CCRF-CEM Prednisolone and MG132 treatments at 4h

ABSTRACT: Background: The combination of Proteasome inhibitor with Glucocorticoid is one of the most promising antileukemic treatments. Both agents act through pluripotent signal mediators. The two types of agents inhibit key signals that are considered crucial to their effects on malignant cells. Methodology/Principal Findings: Combined use of the two reagents on the lymphoblastic leukemia cell line CCRF-CEM has a range of effects on the viability that depend on the dose and the time used. Even though both reagents are capable of enhancing cell death on the CEM cell line, no combinatorial increase in cell death is detectable, until after the first 120 hours of treatment. In contrast, there are a number of combinatorial effects on the cell cycle phase distribution of treated cells, which indicates

ORGANISM(S): Homo sapiens

SUBMITTER: George Lambrou 

PROVIDER: E-GEOD-29136 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress